Furthermore, plasma KIM-1 was significantly higher in patients presenting contrast-associated AKI, defined as an increase in serum creatinine of ≥25% or ≥0.5 mg/dL from baseline at 3-5 days after the injection [55]. The gene discussed is HAVCR1; the disease is acute kidney injury.